CRS

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Giovedì, Maggio 9, 2024
Cancer, Investment, Cell, Research, Gene editing, Research and development, Ink, Computational biology, Myasthenia gravis, CRS, Science, Protein engineering, Administration, Rejection, IPSC, CD19, Autoimmune disease, Bristol Myers Squibb, Patient, Acquisition, Pharming, NHL, Century, Malignancy, BMS, AACR, SLE, Therapy, Lymphoid leukemia, GAAP, BCMA, NK, Pharmaceutical industry

Century’s core Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells.

Key Points: 
  • Century’s core Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells.
  • In April 2024, the Company announced plans to expand clinical development of CNTY-101 into additional autoimmune disease indications beyond SLE.
  • In the second half of 2024, Century intends to submit additional regulatory filings for CNTY-101 in autoimmune disease indications with limited current treatment options and high unmet need.
  • Century plans to share additional data from its Phase 1 ELiPSE-1 trial in R/R non-Hodgkin lymphoma (NHL) at the upcoming ASCO Annual Meeting, being held May 31-June 4, 2024, in Chicago, IL.

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

Retrieved on: 
Mercoledì, Maggio 8, 2024
CD3, Patient, Arthralgia, EDT, HNSCC, CRS, Safety, Pancreatic cancer, Itch, RECIST, PDT, CRC, Trial of the century, Tumor microenvironment, Webcast, Tenosynovitis, Therapy, Vomiting, Arthritis, Rash, Head, Neoplasm, EGFR, Cancer, NSCLC, SAN, Amgen, Lung cancer, Pharmaceutical industry

“These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.

Key Points: 
  • “These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.
  • CX-904 Phase 1a dose escalation and optimization continue, with future enrollment focused on determining a recommended Phase 2 dose, or doses.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • These additional data will inform discussions with CytomX partner, Amgen, towards initiation of Phase 1b expansion cohorts in specific EGFR positive tumor types.

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Maggio 8, 2024
MSD, Investment, Pancreatic cancer, Research, TCE, CRC, Trial of the century, Webcast, Drug discovery, EGFR, Bladder cancer, Cancer, CRS, Cytokine, Tumor microenvironment, ADC, Vomiting, Therapeutic index, Kidney, Bristol Myers Squibb, Therapy, Biotechnology, Spacecraft, SAN, Arthralgia, Safety, Pembrolizumab, RECIST, Arthritis, GLP, Melanoma, BMS, Toxicology, CD3, EDT, Itch, Merck & Co., PDT, Camptothecin, Patient, Rash, Head, Epithelial cell adhesion molecule, Amgen, Pharmaceutical industry

Initial data anticipated in 2025 -

Key Points: 
  • Initial data anticipated in 2025 -
    - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today reported first quarter 2024 financial results and provided a business update.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • The cash balance as of March 31, 2024, does not include the $10.0 million of Astellas milestone achievements earned in the first quarter of 2024.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Retrieved on: 
Lunedì, Maggio 6, 2024
Sinusitis, CRS, LYRA, Network congestion, Data, Workforce, ITT, Therapy, Nosebleed

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210, a bioabsorbable sinonasal implant (7500µg mometasone furoate), as a six-month treatment for chronic rhinosinusitis (CRS).

Key Points: 
  • WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS).
  • ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210, a bioabsorbable sinonasal implant (7500µg mometasone furoate), as a six-month treatment for chronic rhinosinusitis (CRS).
  • “We are surprised and disappointed by the ENLIGHTEN 1 topline results,” said Maria Palasis, Ph.D., President and Chief Executive Officer, Lyra Therapeutics.
  • The ENLIGHTEN 1 trial is ongoing and data from the 52-week extension phase are expected in Q4 2024.

HAProxy Enterprise 2.9 Sets the Security Standard for Application Delivery

Retrieved on: 
Lunedì, Maggio 6, 2024
Denial-of-service attack, ModSecurity, RADIUS, CRS, DNS, NTP, XSS, Conference, API, Infobip, HAProxy, Data science, Automation, UDP, Organization, Privacy, RFI, WAF, Intelligence, Critical, OWASP, SQL, RSA, Fraud, Online shopping

"The next-generation HAProxy Enterprise WAF protects our public APIs and user portal and makes a valuable improvement to our overall application security posture," said Andro Galinović, Chief Information Security Officer at Infobip.

Key Points: 
  • "The next-generation HAProxy Enterprise WAF protects our public APIs and user portal and makes a valuable improvement to our overall application security posture," said Andro Galinović, Chief Information Security Officer at Infobip.
  • Flexible integration with HAProxy Enterprise's suite of other powerful security layers (including the next-generation HAProxy Enterprise WAF and Global Rate Limiting) allows customers to tailor their protection and enforcement options based on the context provided by the HAProxy Enterprise Bot Management Module and the other security signals available in HAProxy Enterprise.
  • The release of HAProxy Enterprise 2.9 reinforces HAProxy Technologies’ position as the industry leader in application delivery and security.
  • Application teams using another load balancer or application delivery controller can request a free trial that includes all features of the HAProxy Enterprise suite with no performance limitations.

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Lunedì, Maggio 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Carnegie Investment Counsel Expands Advisor Opportunities in Key Markets

Retrieved on: 
Mercoledì, Maggio 8, 2024
CRS, Fidelity, Partnership, RIA, Form, Multimedia, Marketing, Ball, Financial adviser

Key highlights for prospective advisors include:

Key Points: 
  • Key highlights for prospective advisors include:
    Comprehensive Support: Carnegie Investment Counsel offers dedicated marketing, business development, and back-office support, enabling advisors to focus on client relationships.
  • Ownership Potential: Carnegie Investment Counsel offers competitive compensation and benefits, including equity participation, fostering long-term career growth and ownership opportunities.
  • For more information about advisor opportunities at Carnegie Investment Counsel, please contact Gary Wagner at [email protected] or (216) 367-4106.
  • Carnegie Investment Counsel ("Carnegie") has been serving investors since 1974, founded by Prescott, Ball & Turben.

AHN, Innovation Works AlphaLab Health Joint Venture Receives $10 Million Grant to Create Revolving Investment Fund

Retrieved on: 
Martedì, Maggio 7, 2024
Investment, CRS, Community health, IW, Infection, Cytokine release syndrome, Machine learning, Immunotherapy, Innovation, MD, Partnership, AHN, Allegheny Health Network, Obstructive sleep apnea, Immune system, OSA

BELLEVUE, Pa., May 7, 2024 /PRNewswire-PRWeb/ -- AlphaLab Health, an accelerator program developed by Innovation Works and Allegheny Health Network for life-sciences startups in the Pittsburgh region, has received a $10 million grant from an anonymous donor to create an evergreen fund.

Key Points: 
  • The grant establishes the AlphaLab Health Revolving Investment Fund, which will support startups in the accelerator program.
  • The investment returns generated by the fund will create a permanent, self-sustaining source of revenue that will be reinvested into future AlphaLab startups.
  • AlphaLab Health is based at Allegheny Health Network (AHN) Suburban, the former Bellevue acute-care hospital that has been reinvented as a community innovation hub.
  • "This significant grant will propel AlphaLab Health into the next decade of health care innovation and beyond," said Mitch Beckman, Chief Development Officer at Highmark Health, parent company of AHN.